Mayinglong Pharmaceutical Group Co Ltd (600993) - Total Liabilities
Based on the latest financial reports, Mayinglong Pharmaceutical Group Co Ltd (600993) has total liabilities worth CN¥906.06 Million CNY (≈ $132.59 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Mayinglong Pharmaceutical Group Co Ltd to track the company's year-over-year net asset growth rate.
Mayinglong Pharmaceutical Group Co Ltd - Total Liabilities Trend (2001–2025)
This chart illustrates how Mayinglong Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Mayinglong Pharmaceutical Group Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
Mayinglong Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Mayinglong Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nusantara Sawit Sejahtera
JK:NSSS
|
Indonesia | Rp2.26 Trillion |
|
Meridianlink Inc
NYSE:MLNK
|
USA | $544.29 Million |
|
E-Mart
KO:139480
|
Korea | ₩21.01 Trillion |
|
DOMS Industries Limited
NSE:DOMS
|
India | Rs4.21 Billion |
|
Sociedad Matriz SAAM SA
SN:SMSAAM
|
Chile | CL$727.12 Million |
|
Métropole Télévision S.A.
PA:MMT
|
France | €641.20 Million |
|
Northking Information Technology Co
SHE:002987
|
China | CN¥586.97 Million |
|
Aryzta AG
SW:ARYN
|
Switzerland | CHF1.33 Billion |
Liability Composition Analysis (2001–2025)
This chart breaks down Mayinglong Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 600993 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mayinglong Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mayinglong Pharmaceutical Group Co Ltd (2001–2025)
The table below shows the annual total liabilities of Mayinglong Pharmaceutical Group Co Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥921.49 Million ≈ $134.84 Million |
-6.03% |
| 2024-12-31 | CN¥980.66 Million ≈ $143.50 Million |
+2.19% |
| 2023-12-31 | CN¥959.62 Million ≈ $140.42 Million |
-33.30% |
| 2022-12-31 | CN¥1.44 Billion ≈ $210.54 Million |
+77.03% |
| 2021-12-31 | CN¥812.72 Million ≈ $118.93 Million |
-11.65% |
| 2020-12-31 | CN¥919.89 Million ≈ $134.61 Million |
+41.42% |
| 2019-12-31 | CN¥650.49 Million ≈ $95.19 Million |
+13.19% |
| 2018-12-31 | CN¥574.67 Million ≈ $84.09 Million |
+18.98% |
| 2017-12-31 | CN¥482.99 Million ≈ $70.68 Million |
+0.65% |
| 2016-12-31 | CN¥479.88 Million ≈ $70.22 Million |
-8.30% |
| 2015-12-31 | CN¥523.31 Million ≈ $76.58 Million |
+7.48% |
| 2014-12-31 | CN¥486.89 Million ≈ $71.25 Million |
+5.57% |
| 2013-12-31 | CN¥461.22 Million ≈ $67.49 Million |
+12.61% |
| 2012-12-31 | CN¥409.56 Million ≈ $59.93 Million |
+21.28% |
| 2011-12-31 | CN¥337.70 Million ≈ $49.42 Million |
+4.98% |
| 2010-12-31 | CN¥321.68 Million ≈ $47.07 Million |
-16.25% |
| 2009-12-31 | CN¥384.11 Million ≈ $56.21 Million |
+31.79% |
| 2008-12-31 | CN¥291.46 Million ≈ $42.65 Million |
+22.19% |
| 2007-12-31 | CN¥238.53 Million ≈ $34.90 Million |
-4.79% |
| 2006-12-31 | CN¥250.53 Million ≈ $36.66 Million |
+42.79% |
| 2005-12-31 | CN¥175.45 Million ≈ $25.67 Million |
+34.20% |
| 2004-12-31 | CN¥130.74 Million ≈ $19.13 Million |
-4.29% |
| 2003-12-31 | CN¥136.61 Million ≈ $19.99 Million |
-13.86% |
| 2002-12-31 | CN¥158.59 Million ≈ $23.21 Million |
+6.52% |
| 2001-12-31 | CN¥148.88 Million ≈ $21.79 Million |
-- |
About Mayinglong Pharmaceutical Group Co Ltd
Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. The company offers functional cosmetics, functional care products and food, Chinese herbal medicines, and medical devices. It also manufactures, processes, and sells medicinal packaging materials, cosmetics, and Chinese medicines; and offers… Read more